TRIAL DETAIL
A Study of the Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors That Are Non-Curable With Standard Therapy
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study of the Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors That Are Non-Curable With Standard Therapy |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 02/01/2006 |
Age of Trial (yrs) 18.2 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
0510000723 |
|||
Sponsor: |
Yale University
Pfizer |
|||
Patient Contact: |
Linda Rink, R.N.
Sally Ruta, B.S., LPN |
|||
Contact email: |
Linda.Rink@yale.edu |
|||
Contact Phone: |
203 785-6128 |
|||
Randomized: |
||||
IV or Oral: |
||||
Trial Notes: |
Primary Outcome Measures: * To determine the maximum tolerated dose of sirolimus when combined with a standard dose and schedule of Sutent(R) * To obtain preliminary experience with dynamic MR imaging of tumor blood flow using the combination of Sutent(R) and sirolimus * To provide preliminary data on dose effects of the combination on serum levels of VEGF and circulating endothelial cells * To obtain preliminary information on the efficacy of Sutent(R)in combination with sirolimus in treating malignancies using RECIST criteria |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
333 Cedar St |
New Haven |
CT |
06510 |
USA |